```
<!--StartFragment-->RESULT 1
AAY05069
TD
    AAY05069 standard; protein; 205 AA.
AC
    AAY05069;
XX
DT
    16-JUN-1999 (first entry)
XX
DΕ
    Human PIGR-2 protein sequence.
XX
    PIGR-2; human; autoimmune disease; rheumatoid arthritis; psoriasis;
KW
KW
    Multiple Sclerosis; Systemic Lupus Erythematosus; diagnosis; therapy;
    Inflammatory Bowel Disease.
KW
XX
    Homo sapiens.
XX
    EP905237-A2.
PΝ
XX
    31-MAR-1999.
PD
XX
PF
    07-AUG-1998;
                   98EP-00306323.
XX
    25-AUG-1997;
                   97US-0056774P.
PR
PR
    21-NOV-1997;
                   97US-00976293.
XX
PA
    (SMIK ) SMITHKLINE BEECHAM CORP.
XX
    Sweet RW, Truneh A, Wu S;
PΙ
XX
    WPI; 1999-192665/17.
DR
    N-PSDB; AAX28250.
DR
XX
    New polypeptides encoding human PIGR-2 useful for treating diseases such
PΤ
PТ
    as rheumatoid arthritis and multiple sclerosis.
XX
PS
    Claim 11; Page 17; 23pp; English.
XX
CC
    This sequence is the human PIGR-2 protein of the invention. Autoimmune
CC
    diseases involving altered expression or activity of PIGR-2 may include
CC
    rheumatoid arthritis, Multiple Sclerosis, psoriasis, Systemic Lupus
CC
    Erythematosus and Inflammatory Bowel Disease. These diseases can be
CC
    diagnosed or susceptibility to them predicted by: (1) determining whether
CC
    there is a mutation in the genomic copy of the gene encoding PIGR-2; or
CC
    (2) measuring the amount of PIGR-2 in a sample derived from the patient.
CC
    Patients deficient in PIGR-2 can be treated by administering either the
CC
    PIGR-2 DNA or its complement or an agonist of PIGR-2 to the patient.
    Patients with excessive expression or activity of PIGR-2 can be treated
CC
    by administering an antagonist of PIGR-2, an antisense nucleic acid
CC
    molecule which inhibits the expression of PIGR-2 or administering
    sufficient PIGR-2 to compete with the endogenous activity. PIGR-2 can be
CC
    used to identify its agonists by contacting a cell expressing PIGR-2 with
CC
    a candidate compound in the presence of a signal system and noting the
    candidate as an agonist if a signal is produced. The same method can be
CC
    used to identify antagonists of PIGR-2 but the presence of an antagonist
CC
    is indicated by a decrease in production of the signal. Antibodies
    against PIGR-2 may be used to isolate or identify clones expressing PIGR-
CC
CC
XX
    Sequence 205 AA;
                        100.0%; Score 1108; DB 2; Length 205;
  Query Match
 Best Local Similarity 100.0%; Pred. No. 2.2e-95;
 Matches 205; Conservative
                               0; Mismatches
                                                0;
                                                    Indels
                                                              0; Gaps
                                                                          0:
           1 MWLLPALLLLCLSGCLSLKGPGSVTGTAGDSLTVWCQYESMYKGYNKYWCRGQYDTSCES 60
QV
             1 \ \texttt{MWLLPALLLLCLSGCLSLKGPGSVTGTAGDSLTVWCQYESMYKGYNKYWCRGQYDTSCES} \ \ 60
Db
          61 IVETKGEEKVERNGRVSIRDHPEALAFTVTMQNLNEDDAGSYWCKIQTVWVLDSWSRDPS 120
             61 IVETKGEEKVERNGRVSIRDHPEALAFTVTMQNLNEDDAGSYWCKIQTVWVLDSWSRDPS 120
Db
         121 DLVRVYVSPAITTPRRTTHPATPPIFLVVNPGRNLSTREVLTQNSGFRLSSPHFLLVVLL 180
Q.V
             Db
         121 DLVRVYVSPAITTPRRTTHPATPPIFLVVNPGRNLSTREVLTQNSGFRLSSPHFLLVVLL 180
```

```
        Qy
        181
        KLPLLLSMLGAVFWVNRPQWAPPGR
        205

        LILINITION
        181
        KLPLLLSMLGAVFWVNRPQWAPPGR
        205
```

<!--EndFragment-->